Felodipine - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (13)Enzymes (6)Transporters (1)

Targets (13)Enzymes (6)Transporters (1)Biointeractions (21)

Identification

Name

Felodipine

Accession Number

DB01023 (APRD00374)

Type

Small Molecule

Groups

Approved, Investigational

Description

Felodipine is a long-acting 1,4-dihydropyridine calcium channel blocker (CCB)b. It acts primarily on vascular smooth muscle cells by stabilizing voltage-gated L-type calcium channels in their inactive conformation. By inhibiting the influx of calcium in smooth muscle cells, felodipine prevents calcium-dependent myocyte contraction and vasoconstriction. Felodipine is the most potent CCB in use and is unique in that it exhibits fluorescent activity. In addition to binding to L-type calcium channels, felodipine binds to a number of calcium-binding proteins, exhibits competitive antagonism of the mineralcorticoid receptor, inhibits the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase, and blocks calcium influx through voltage-gated T-type calcium channels. Felodipine is used to treat mild to moderate essential hypertension.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

(+-)-Ethyl methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate

3-Ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydro-3,5-pyridinedicarboxylate

4-(2,3-Dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester

Felodipina

Felodipine

Felodipinum

External IDs

Not Available

Product Ingredients

Not Available

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Felodipineextended-release Tablets	Tablet, extended release	2.5 mg/1	Oral	Ranbaxy Inc.	2008-09-10	Not applicable	US
Felodipineextended-release Tablets	Tablet, extended release	5 mg/1	Oral	Ranbaxy Inc.	2008-09-10	Not applicable	US
Felodipineextended-release Tablets	Tablet, extended release	10 mg/1	Oral	Ranbaxy Inc.	2008-09-10	Not applicable	US
Plendil	Tablet, extended release	2.5 mg/1	Oral	Astra Zeneca Lp	1994-10-04	2016-11-04	US
Plendil	Tablet, extended release	10 mg/1	Oral	bryant ranch prepack	1991-09-16	Not applicable	US
Plendil	Tablet, extended release	5 mg/1	Oral	Astra Zeneca Lp	1991-09-16	2016-11-04	US
Plendil	Tablet, extended release	10 mg/1	Oral	Astra Zeneca Lp	1991-09-16	2016-11-04	US
Plendil 10 mg	Tablet, extended release	10 mg	Oral	Astra Zeneca	1992-12-31	Not applicable	Canada
Plendil 2.5 mg	Tablet, extended release	2.5 mg	Oral	Astra Zeneca	1994-12-31	Not applicable	Canada
Plendil 5 mg	Tablet, extended release	5 mg	Oral	Astra Zeneca	1992-12-31	Not applicable	Canada
Renedil	Tablet, extended release	10 mg	Oral	Sanofi Aventis	1997-05-28	2014-06-23	Canada
Renedil	Tablet, extended release	2.5 mg	Oral	Sanofi Aventis	1997-03-24	2014-06-23	Canada
Renedil	Tablet, extended release	5 mg	Oral	Sanofi Aventis	1997-04-21	2014-06-23	Canada
Renedil Srt 10mg	Tablet, extended release	10 mg	Oral	Hoechst Canada Inc.	1992-12-31	1996-08-29	Canada
Renedil Srt 10mg	Tablet, extended release	10 mg	Oral	Hoechst Roussel Canada Inc.	1994-12-31	1999-08-11	Canada
Renedil Srt 2.5mg	Tablet, extended release	2.5 mg	Oral	Hoechst Canada Inc.	1994-12-31	1997-08-05	Canada
Renedil Srt 2.5mg	Tablet, extended release	2.5 mg	Oral	Hoechst Roussel Canada Inc.	1994-12-31	1999-08-11	Canada
Renedil Srt 5mg	Tablet, extended release	5 mg	Oral	Hoechst Canada Inc.	1992-12-31	1996-08-29	Canada
Renedil Srt 5mg	Tablet, extended release	5 mg	Oral	Hoechst Roussel Canada Inc.	1994-12-31	1999-08-11	Canada
Sandoz Felodipine	Tablet, extended release	10 mg	Oral	Sandoz Canada Incorporated	2006-08-15	Not applicable	Canada
Sandoz Felodipine	Tablet, extended release	5 mg	Oral	Sandoz Canada Incorporated	2006-08-15	Not applicable	Canada

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Apo-felodipine	Tablet, extended release	5 mg	Oral	Apotex Corporation	2016-04-22	Not applicable	Canada
Apo-felodipine	Tablet, extended release	10 mg	Oral	Apotex Corporation	2016-04-22	Not applicable	Canada
Apo-felodipine	Tablet, extended release	2.5 mg	Oral	Apotex Corporation	2016-04-22	Not applicable	Canada
Felodipine	Tablet, extended release	5 mg/1	Oral	Amerincan Health Packaging	2014-12-15	Not applicable	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Av Kare, Inc.	2014-03-31	2016-01-15	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Carilion Materials Management	2004-11-02	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Wockhardt	2010-12-05	Not applicable	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	2016-08-19	Not applicable	US
Felodipine	Tablet, extended release	5 mg/1	Oral	Mesource Pharmaceuticals	2011-11-28	Not applicable	US
Felodipine	Tablet, extended release	10 mg/1	Oral	Heritage	2013-11-08	Not applicable	US
Felodipine	Tablet, extended release	2.5 mg/1	Oral	Qualitest	2009-03-31	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Wockhardt	2010-12-05	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Mylan Pharmaceuticals	2008-04-18	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Physicians Total Care, Inc.	2005-01-21	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	A S Medication Solutions	2010-12-20	2017-06-20	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Mylan Institutional	2008-05-01	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2009-11-16	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Aurobindo Pharma	2013-01-17	Not applicable	US
Felodipine	Tablet, extended release	5 mg/1	Oral	Heritage	2013-11-08	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Wockhardt	2010-12-05	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2010-12-20	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Mesource Pharmaceuticals	2010-12-20	Not applicable	US
Felodipine	Tablet, extended release	10 mg/1	Oral	A S Medication Solutions	2011-11-28	2017-06-20	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Citron Pharma LLC	2013-01-17	Not applicable	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Wockhardt	2010-12-05	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Sun Pharmaceutical Industries Limited	2004-11-02	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Richmond Pharmaceuticals	2004-11-02	Not applicable	US
Felodipine	Tablet, extended release	5 mg/1	Oral	Torrent Pharmaceuticals Limited	2011-11-28	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Mylan Pharmaceuticals	2008-04-18	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Physicians Total Care, Inc.	2005-03-22	Not applicable	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2010-12-20	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Av Kare, Inc.	2014-03-31	2016-01-15	US
Felodipine	Tablet, extended release	10 mg/1	Oral	A S Medication Solutions	2011-11-28	2017-06-20	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Citron Pharma LLC	2013-01-17	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	2016-08-19	Not applicable	US
Felodipine	Tablet, extended release	5 mg/1	Oral	Remedy Repack	2011-04-20	2016-10-13	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	2004-11-02	Not applicable	US
Felodipine	Tablet, extended release	5 mg/1	Oral	Qualitest	2011-12-15	Not applicable	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Aurobindo Pharma	2013-01-17	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	bryant ranch prepack	2004-11-02	Not applicable	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Sun Pharmaceutical Industries Limited	2004-11-02	Not applicable	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Richmond Pharmaceuticals	2004-11-02	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Ncs Health Care Of Ky, Inc Dba Vangard Labs	2009-11-16	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Carilion Materials Management	2010-12-20	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Wockhardt	2010-12-05	Not applicable	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Mylan Pharmaceuticals	2008-04-18	Not applicable	US
Felodipine	Tablet, film coated	2.5 mg/1	Oral	Physicians Total Care, Inc.	2005-11-08	Not applicable	US
Felodipine	Tablet, extended release	10 mg/1	Oral	Torrent Pharmaceuticals Limited	2011-11-28	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Qualitest	2011-12-15	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Aurobindo Pharma	2013-01-17	Not applicable	US
Felodipine	Tablet, extended release	2.5 mg/1	Oral	Heritage	2013-11-08	Not applicable	US
Felodipine	Tablet, film coated, extended release	2.5 mg/1	Oral	Wockhardt	2010-12-05	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Glenmark Pharmaceuticals Inc.,Usa	2010-12-20	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Av Kare, Inc.	2014-03-31	2016-01-15	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	A S Medication Solutions	2004-11-02	2017-06-20	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Citron Pharma LLC	2013-01-17	Not applicable	US
Felodipine	Tablet, film coated, extended release	10 mg/1	Oral	Jubilant Cadista Pharmaceuticals Inc.	2016-08-19	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Mylan Institutional	2008-05-01	Not applicable	US
Felodipine	Tablet, extended release	2.5 mg/1	Oral	bryant ranch prepack	2011-11-28	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Sun Pharmaceutical Industries Limited	2004-11-02	Not applicable	US
Felodipine	Tablet, film coated, extended release	5 mg/1	Oral	Richmond Pharmaceuticals	2004-11-02	Not applicable	US
Felodipine	Tablet, extended release	2.5 mg/1	Oral	Torrent Pharmaceuticals Limited	2011-11-28	Not applicable	US

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Name	Company
Felodur ER	Not Available
Felogard	Not Available
Penedil	Not Available
Plendil Depottab	AstraZeneca
Plendil ER	AstraZeneca
Plendil Retard	AstraZeneca
Splendil	Not Available

Brand mixtures

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Altace Plus Felodipine 2.5mg + 2.5mg	Felodipine Ramipril	Tablet	Oral	Sanofi Aventis	2006-06-27	2012-10-10	Canada
Altace Plus Felodipine 5mg + 5mg	Felodipine Ramipril	Tablet	Oral	Sanofi Aventis	2006-06-27	2012-10-15	Canada

Categories

UNII

OL961R6O2C

CAS number

72509-76-3

Weight

Average: 384.254
Monoisotopic: 383.069113515

Chemical Formula

C₁₈H₁₉Cl₂NO₄

InChI Key

RZTAMFZIAATZDJ-UHFFFAOYSA-N

InChI

InChI=1S/C18H19Cl2NO4/c1-5-25-18(23)14-10(3)21-9(2)13(17(22)24-4)15(14)11-7-6-8-12(19)16(11)20/h6-8,15,21H,5H2,1-4H3

IUPAC Name

3-ethyl 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate

SMILES

CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC

Pharmacology

Indication

For the treatment of mild to moderate essential hypertension.

Structured Indications

Hypertensive

Pharmacodynamics

Felodipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. There are at least five different types of calcium channels in Homo sapiens: L-, N-, P/Q-, R- and T-type. It was widely accepted that CCBs target L-type calcium channels, the major channel in muscle cells that mediates contraction; however, some studies have shown that felodipine also binds to and inhibits T-type calcium channels. T-type calcium channels are most commonly found on neurons, cells with pacemaker activity and on osteocytes. The pharmacologic significance of T-type calcium channel blockade is unknown. Felodipine also binds to calmodulin and inhibits calmodulin-dependent calcium release from the sarcoplasmic reticulum. The effect of this interaction appears to be minor. Another study demonstrated that felodipine attenuates the activity of calmodulin-dependent cyclic nucleotide phosphodiesterase (CaMPDE) by binding to the PDE-1B1 and PDE-1A2 enzyme subunits. CaMPDE is one of the key enzymes involved in cyclic nucleotides and calcium second messenger systems. Felodipine also acts as an antagonist to the mineralcorticoid receptor by competing with aldosterone for binding and blocking aldosterone-induced coactivator recruitment of the mineralcorticoid receptor. Felodipine is able to bind to skeletal and cardiac muscle isoforms of troponin C, one of the key regulatory proteins in muscle contraction. Though felodipine exhibits binding to many endogenous molecules, its vasodilatory effects are still thought to be brought about primarily through inhibition of voltage-gated L-type calcium channels. Similar to other DHP CCBs, felodipine binds directly to inactive calcium channels stabilizing their inactive conformation. Since arterial smooth muscle depolarizations are longer in duration than cardiac muscle depolarizations, inactive channels are more prevalent in smooth muscle cells. Alternative splicing of the alpha-1 subunit of the channel gives felodipine additional arterial selectivity. At therapeutic sub-toxic concentrations, felodipine has little effect on cardiac myocytes and conduction cells.

Mechanism of action

Felodipine decreases arterial smooth muscle contractility and subsequent vasoconstriction by inhibiting the influx of calcium ions through voltage-gated L-type calcium channels. It reversibly competes against nitrendipine and other DHP CCBs for DHP binding sites in vascular smooth muscle and cultured rabbit atrial cells. Calcium ions entering the cell through these channels bind to calmodulin. Calcium-bound calmodulin then binds to and activates myosin light chain kinase (MLCK). Activated MLCK catalyzes the phosphorylation of the regulatory light chain subunit of myosin, a key step in muscle contraction. Signal amplification is achieved by calcium-induced calcium release from the sarcoplasmic reticulum through ryanodine receptors. Inhibition of the initial influx of calcium decreases the contractile activity of arterial smooth muscle cells and results in vasodilation. The vasodilatory effects of felodipine result in an overall decrease in blood pressure. Felodipine may be used to treat mild to moderate essential hypertension.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Voltage-dependent L-type calcium channel subunit alpha-1C	Protein	yes	inhibitor	Human	Q13936	details
Voltage-dependent calcium channel subunit alpha-2/delta-1	Protein	yes	inhibitor	Human	P54289	details
Voltage-dependent L-type calcium channel subunit beta-2	Protein	yes	inhibitor	Human	Q08289	details
Voltage-dependent L-type calcium channel subunit alpha-1D	Protein	yes	inhibitor	Human	Q01668	details
Voltage-dependent L-type calcium channel subunit alpha-1S	Protein	yes	inhibitor	Human	Q13698	details
Voltage-dependent T-type calcium channel subunit alpha-1H	Protein	unknown	inhibitor	Human	O95180	details
Voltage-dependent calcium channel subunit alpha-2/delta-2	Protein	unknown	inhibitor	Human	Q9NY47	details
Calmodulin	Protein	unknown	other	Human	P0DP23	details
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B	Protein	unknown	inhibitor	Human	Q01064	details
Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A	Protein	unknown	inhibitor	Human	P54750	details
Mineralocorticoid receptor	Protein	unknown	antagonist	Human	P08235	details
Troponin C, skeletal muscle	Protein	unknown	other	Human	P02585	details
Troponin C, slow skeletal and cardiac muscles	Protein	unknown	other	Human	P63316	details

Absorption

Is completely absorbed from the gastrointestinal tract; however, extensive first-pass metabolism through the portal circulation results in a low systemic availability of 15%. Bioavailability is unaffected by food.

Volume of distribution

10 L/kg

Protein binding

99%, primarily to the albumin fraction.

Metabolism

Hepatic metabolism primarily via cytochrome P450 3A4. Six metabolites with no appreciable vasodilatory effects have been identified.

Substrate	Enzymes	Product
Felodipine	Cytochrome P450 3A4	dehydrofelodipine	Details

Route of elimination

Although higher concentrations of the metabolites are present in the plasma due to decreased urinary excretion, these are inactive. Animal studies have demonstrated that felodipine crosses the blood-brain barrier and the placenta.

Half life

17.5-31.5 hours in hypertensive patients; 19.1-35.9 hours in elderly hypertensive patients; 8.5-19.7 in healthy volunteers.

Clearance

0.8 L/min [Young healthy subjects]

Toxicity

Symptoms of overdose include excessive peripheral vasodilation with marked hypotension and possibly bradycardia. Oral rat LD₅₀ is 1050 mg/kg.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category	SMPDB ID
Felodipine Action Pathway	Drug action	SMP00377
Felodipine Metabolism Pathway	Drug metabolism	SMP00619

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2-HYDROXY-1,4-NAPHTHOQUINONE	The risk or severity of adverse effects can be increased when 2-HYDROXY-1,4-NAPHTHOQUINONE is combined with Felodipine.	Experimental
2-mercaptobenzothiazole	The risk or severity of adverse effects can be increased when 2-mercaptobenzothiazole is combined with Felodipine.	Vet Approved
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Felodipine.	Experimental
Acebutolol	The risk or severity of adverse effects can be increased when Felodipine is combined with Acebutolol.	Approved
Acetaminophen	The serum concentration of Acetaminophen can be increased when it is combined with Felodipine.	Approved
Acetazolamide	The risk or severity of adverse effects can be increased when Felodipine is combined with Acetazolamide.	Approved, Vet Approved
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be increased when it is combined with Felodipine.	Approved, Vet Approved
Afatinib	The serum concentration of Afatinib can be increased when it is combined with Felodipine.	Approved
Aldesleukin	The risk or severity of adverse effects can be increased when Aldesleukin is combined with Felodipine.	Approved
Aldosterone	The serum concentration of Aldosterone can be increased when it is combined with Felodipine.	Experimental
Alfuzosin	Alfuzosin may increase the hypotensive activities of Felodipine.	Approved, Investigational
Aliskiren	The risk or severity of adverse effects can be increased when Felodipine is combined with Aliskiren.	Approved, Investigational
Alitretinoin	The serum concentration of Alitretinoin can be increased when it is combined with Felodipine.	Approved, Investigational
Almotriptan	The metabolism of Almotriptan can be decreased when combined with Felodipine.	Approved, Investigational
Alprenolol	Alprenolol may increase the hypotensive activities of Felodipine.	Approved, Withdrawn
Ambrisentan	The serum concentration of Ambrisentan can be increased when it is combined with Felodipine.	Approved, Investigational
Amifostine	Felodipine may increase the hypotensive activities of Amifostine.	Approved, Investigational
Amiloride	The risk or severity of adverse effects can be increased when Amiloride is combined with Felodipine.	Approved
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Felodipine.	Approved, Withdrawn
Amiodarone	The metabolism of Felodipine can be decreased when combined with Amiodarone.	Approved, Investigational
Amitriptyline	The serum concentration of Amitriptyline can be increased when it is combined with Felodipine.	Approved
Amlodipine	The risk or severity of adverse effects can be increased when Amlodipine is combined with Felodipine.	Approved
Amobarbital	Amobarbital may increase the hypotensive activities of Felodipine.	Approved, Illicit
Amodiaquine	The serum concentration of Amodiaquine can be increased when it is combined with Felodipine.	Approved
Amorolfine	The risk or severity of adverse effects can be increased when Amorolfine is combined with Felodipine.	Approved
Amphotericin B	The risk or severity of adverse effects can be increased when Amphotericin B is combined with Felodipine.	Approved, Investigational
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Felodipine.	Approved
Amyl Nitrite	The risk or severity of adverse effects can be increased when Felodipine is combined with Amyl Nitrite.	Approved
Anidulafungin	The risk or severity of adverse effects can be increased when Anidulafungin is combined with Felodipine.	Approved, Investigational
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Felodipine.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Felodipine.	Approved
Apomorphine	The risk or severity of adverse effects can be increased when Felodipine is combined with Apomorphine.	Approved, Investigational
Apraclonidine	The risk or severity of adverse effects can be increased when Apraclonidine is combined with Felodipine.	Approved
Aprepitant	The serum concentration of Felodipine can be increased when it is combined with Aprepitant.	Approved, Investigational
Aripiprazole	Aripiprazole may increase the hypotensive activities of Felodipine.	Approved, Investigational
Arotinolol	The risk or severity of adverse effects can be increased when Felodipine is combined with Arotinolol.	Approved
Arsenic trioxide	The serum concentration of Arsenic trioxide can be increased when it is combined with Felodipine.	Approved, Investigational
Artemether	The risk or severity of adverse effects can be increased when Artemether is combined with Felodipine.	Approved
Atazanavir	The metabolism of Felodipine can be decreased when combined with Atazanavir.	Approved, Investigational
Atenolol	The risk or severity of adverse effects can be increased when Atenolol is combined with Felodipine.	Approved
Atomoxetine	The metabolism of Felodipine can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The metabolism of Atorvastatin can be decreased when combined with Felodipine.	Approved
Atosiban	The risk or severity of adverse effects can be increased when Felodipine is combined with Atosiban.	Approved
Atracurium besylate	Felodipine may increase the neuromuscular blocking activities of Atracurium besylate.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Felodipine.	Approved, Investigational
Azelastine	The metabolism of Azelastine can be decreased when combined with Felodipine.	Approved
Azilsartan medoxomil	The risk or severity of adverse effects can be increased when Felodipine is combined with Azilsartan medoxomil.	Approved
Bafilomycin A1	The risk or severity of adverse effects can be increased when Bafilomycin A1 is combined with Felodipine.	Experimental
Barbexaclone	Barbexaclone may increase the hypotensive activities of Felodipine.	Experimental
Barbital	Barbital may increase the hypotensive activities of Felodipine.	Illicit
Barnidipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Barnidipine.	Approved
Benazepril	The risk or severity of adverse effects can be increased when Benazepril is combined with Felodipine.	Approved, Investigational
Bendroflumethiazide	The risk or severity of adverse effects can be increased when Bendroflumethiazide is combined with Felodipine.	Approved
Benmoxin	Benmoxin may increase the hypotensive activities of Felodipine.	Withdrawn
Benzoic Acid	The risk or severity of adverse effects can be increased when Benzoic Acid is combined with Felodipine.	Approved
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Felodipine.	Approved
Bepridil	Felodipine may increase the hypotensive activities of Bepridil.	Approved, Withdrawn
Beraprost	The metabolism of Beraprost can be decreased when combined with Felodipine.	Investigational
Betamethasone	The serum concentration of Betamethasone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Betaxolol	The risk or severity of adverse effects can be increased when Betaxolol is combined with Felodipine.	Approved
Bethanidine	Bethanidine may increase the hypotensive activities of Felodipine.	Approved
Bexarotene	The serum concentration of Felodipine can be decreased when it is combined with Bexarotene.	Approved, Investigational
Bifonazole	The risk or severity of adverse effects can be increased when Bifonazole is combined with Felodipine.	Approved
Bimatoprost	Bimatoprost may increase the hypotensive activities of Felodipine.	Approved, Investigational
Bisoprolol	The risk or severity of adverse effects can be increased when Bisoprolol is combined with Felodipine.	Approved
Boceprevir	The metabolism of Felodipine can be decreased when combined with Boceprevir.	Withdrawn
Bortezomib	The metabolism of Felodipine can be decreased when combined with Bortezomib.	Approved, Investigational
Bosentan	The serum concentration of Felodipine can be decreased when it is combined with Bosentan.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Felodipine.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Felodipine.	Approved
Bretylium	The risk or severity of adverse effects can be increased when Felodipine is combined with Bretylium.	Approved
Brimonidine	Brimonidine may increase the antihypertensive activities of Felodipine.	Approved
Brimonidine	The risk or severity of adverse effects can be increased when Brimonidine is combined with Felodipine.	Approved
Bromocriptine	The serum concentration of Bromocriptine can be increased when it is combined with Felodipine.	Approved, Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Felodipine.	Approved
Bucindolol	Bucindolol may increase the hypotensive activities of Felodipine.	Investigational
Bumetanide	The risk or severity of adverse effects can be increased when Bumetanide is combined with Felodipine.	Approved
Bupivacaine	The risk or severity of adverse effects can be increased when Felodipine is combined with Bupivacaine.	Approved, Investigational
Bupranolol	Felodipine may increase the hypotensive activities of Bupranolol.	Approved
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Felodipine.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Bupropion can be decreased when combined with Felodipine.	Approved
Butenafine	The risk or severity of adverse effects can be increased when Butenafine is combined with Felodipine.	Approved
Butoconazole	The risk or severity of adverse effects can be increased when Butoconazole is combined with Felodipine.	Approved
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Felodipine.	Approved
Caffeine	The serum concentration of Caffeine can be increased when it is combined with Felodipine.	Approved
Calcium	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium.	Nutraceutical
Calcium Acetate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Acetate.	Approved
Calcium Carbonate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium carbonate.	Approved
Calcium Chloride	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Chloride.	Approved
Calcium Citrate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium citrate.	Approved
Calcium glubionate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium glubionate.	Approved
Calcium Gluceptate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Gluceptate.	Approved
Calcium gluconate	The therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium gluconate.	Approved, Vet Approved
Camptothecin	The serum concentration of Camptothecin can be increased when it is combined with Felodipine.	Experimental
Canagliflozin	The risk or severity of adverse effects can be increased when Felodipine is combined with Canagliflozin.	Approved
Candesartan	The risk or severity of adverse effects can be increased when Candesartan is combined with Felodipine.	Approved
Candicidin	The risk or severity of adverse effects can be increased when Candicidin is combined with Felodipine.	Withdrawn
Candoxatril	Candoxatril may increase the hypotensive activities of Felodipine.	Experimental
Capric acid	The risk or severity of adverse effects can be increased when Decanoic Acid is combined with Felodipine.	Experimental
Captopril	The risk or severity of adverse effects can be increased when Felodipine is combined with Captopril.	Approved
Carbamazepine	The metabolism of Felodipine can be increased when combined with Carbamazepine.	Approved, Investigational
Carbetocin	The risk or severity of adverse effects can be increased when Felodipine is combined with Carbetocin.	Approved
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Felodipine.	Approved
Carbomycin	The metabolism of Felodipine can be decreased when combined with Carbomycin.	Vet Approved
Carfilzomib	The serum concentration of Carfilzomib can be increased when it is combined with Felodipine.	Approved
Caroxazone	Caroxazone may increase the hypotensive activities of Felodipine.	Withdrawn
Carteolol	The risk or severity of adverse effects can be increased when Carteolol is combined with Felodipine.	Approved
Carvedilol	The risk or severity of adverse effects can be increased when Felodipine is combined with Carvedilol.	Approved, Investigational
Caspofungin	The risk or severity of adverse effects can be increased when Caspofungin is combined with Felodipine.	Approved
Celiprolol	Felodipine may increase the hypotensive activities of Celiprolol.	Approved, Investigational
Ceritinib	The serum concentration of Felodipine can be increased when it is combined with Ceritinib.	Approved
Cerivastatin	The serum concentration of Cerivastatin can be increased when it is combined with Felodipine.	Withdrawn
Cerulenin	The risk or severity of adverse effects can be increased when Cerulenin is combined with Felodipine.	Approved
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Felodipine.	Approved, Vet Approved
Chlorothiazide	The risk or severity of adverse effects can be increased when Chlorothiazide is combined with Felodipine.	Approved, Vet Approved
Chloroxine	The risk or severity of adverse effects can be increased when Chloroxine is combined with Felodipine.	Approved
Chlorpromazine	The serum concentration of Chlorpromazine can be increased when it is combined with Felodipine.	Approved, Vet Approved
Chlorthalidone	The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Felodipine.	Approved
Ciclopirox	The risk or severity of adverse effects can be increased when Ciclopirox is combined with Felodipine.	Approved, Investigational
Cilazapril	The risk or severity of adverse effects can be increased when Felodipine is combined with Cilazapril.	Approved
Cilnidipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Cilnidipine.	Approved
Cimetidine	The serum concentration of Felodipine can be increased when it is combined with Cimetidine.	Approved
Ciprofloxacin	The serum concentration of Ciprofloxacin can be increased when it is combined with Felodipine.	Approved, Investigational
Cisapride	The metabolism of Cisapride can be decreased when combined with Felodipine.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be increased when it is combined with Felodipine.	Approved
Citalopram	The serum concentration of Citalopram can be increased when it is combined with Felodipine.	Approved
Clarithromycin	The metabolism of Felodipine can be decreased when combined with Clarithromycin.	Approved
Clemastine	The metabolism of Felodipine can be decreased when combined with Clemastine.	Approved
Clevidipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Clevidipine.	Approved
Clobazam	The serum concentration of Clobazam can be increased when it is combined with Felodipine.	Approved, Illicit
Clofarabine	The risk or severity of adverse effects can be increased when Felodipine is combined with Clofarabine.	Approved, Investigational
Clomifene	The serum concentration of Clomifene can be increased when it is combined with Felodipine.	Approved, Investigational
Clomipramine	The risk or severity of adverse effects can be increased when Felodipine is combined with Clomipramine.	Approved, Vet Approved
Clonidine	The risk or severity of adverse effects can be increased when Clonidine is combined with Felodipine.	Approved
Clopidogrel	The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Felodipine.	Approved, Nutraceutical
Clotrimazole	The risk or severity of adverse effects can be increased when Clotrimazole is combined with Felodipine.	Approved, Vet Approved
Clozapine	The serum concentration of Clozapine can be increased when it is combined with Felodipine.	Approved
Cobicistat	The metabolism of Felodipine can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Felodipine.	Approved
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Felodipine.	Approved
Conivaptan	The serum concentration of Felodipine can be increased when it is combined with Conivaptan.	Approved, Investigational
Conjugated estrogens	The serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Felodipine.	Approved
Cordycepin	The risk or severity of adverse effects can be increased when Cordycepin is combined with Felodipine.	Investigational
Crizotinib	The metabolism of Felodipine can be decreased when combined with Crizotinib.	Approved
Cryptenamine	Cryptenamine may increase the hypotensive activities of Felodipine.	Approved
Cyclophosphamide	The metabolism of Cyclophosphamide can be decreased when combined with Felodipine.	Approved, Investigational
Cyclosporine	The risk or severity of adverse effects can be increased when Cyclosporine is combined with Felodipine.	Approved, Investigational, Vet Approved
Cyclosporine	The metabolism of Felodipine can be decreased when combined with Cyclosporine.	Approved, Investigational, Vet Approved
Cyclothiazide	Cyclothiazide may increase the hypotensive activities of Felodipine.	Approved
Dabigatran etexilate	The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Felodipine.	Approved
Dabrafenib	The serum concentration of Felodipine can be decreased when it is combined with Dabrafenib.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be increased when it is combined with Felodipine.	Approved
Dapagliflozin	The risk or severity of adverse effects can be increased when Felodipine is combined with Dapagliflozin.	Approved
Dapoxetine	Dapoxetine may increase the orthostatic hypotensive activities of Felodipine.	Investigational
Dapsone	The metabolism of Dapsone can be decreased when combined with Felodipine.	Approved, Investigational
Darunavir	The metabolism of Felodipine can be decreased when combined with Darunavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Felodipine.	Approved
Dasatinib	The serum concentration of Felodipine can be increased when it is combined with Dasatinib.	Approved, Investigational
Daunorubicin	The serum concentration of Daunorubicin can be increased when it is combined with Felodipine.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be increased when it is combined with Felodipine.	Approved
Deferasirox	The serum concentration of Felodipine can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The metabolism of Felodipine can be decreased when combined with Delavirdine.	Approved
Deserpidine	Felodipine may increase the hypotensive activities of Deserpidine.	Approved
Desflurane	The risk or severity of adverse effects can be increased when Felodipine is combined with Desflurane.	Approved
Dexamethasone	The serum concentration of Felodipine can be decreased when it is combined with Dexamethasone.	Approved, Investigational, Vet Approved
Dexmedetomidine	The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Felodipine.	Approved, Vet Approved
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Felodipine.	Approved
Diazepam	The serum concentration of Diazepam can be increased when it is combined with Felodipine.	Approved, Illicit, Vet Approved
Diazoxide	Diazoxide may increase the hypotensive activities of Felodipine.	Approved
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Felodipine.	Approved, Vet Approved
Diclofenamide	The risk or severity of adverse effects can be increased when Felodipine is combined with Diclofenamide.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be increased when it is combined with Felodipine.	Approved
Digitoxin	The serum concentration of Digitoxin can be increased when it is combined with Felodipine.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Felodipine.	Approved
Dihydralazine	Felodipine may increase the hypotensive activities of Dihydralazine.	Investigational
Dihydroergotamine	The metabolism of Felodipine can be decreased when combined with Dihydroergotamine.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be increased when it is combined with Felodipine.	Illicit
Diltiazem	The risk or severity of adverse effects can be increased when Diltiazem is combined with Felodipine.	Approved
Dinutuximab	The risk or severity of adverse effects can be increased when Felodipine is combined with Dinutuximab.	Approved
Dipyridamole	The risk or severity of adverse effects can be increased when Dipyridamole is combined with Felodipine.	Approved
Docetaxel	The serum concentration of Docetaxel can be increased when it is combined with Felodipine.	Approved, Investigational
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Dorzolamide	Dorzolamide may increase the hypotensive activities of Felodipine.	Approved
Doxazosin	The risk or severity of adverse effects can be increased when Doxazosin is combined with Felodipine.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Felodipine.	Approved, Investigational
Doxycycline	The metabolism of Felodipine can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronedarone	The metabolism of Felodipine can be decreased when combined with Dronedarone.	Approved
Duloxetine	Felodipine may increase the orthostatic hypotensive activities of Duloxetine.	Approved
Econazole	The risk or severity of adverse effects can be increased when Econazole is combined with Felodipine.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Felodipine.	Approved
Efavirenz	The serum concentration of Felodipine can be decreased when it is combined with Efavirenz.	Approved, Investigational
Efinaconazole	The risk or severity of adverse effects can be increased when Efinaconazole is combined with Felodipine.	Approved
Efonidipine	Felodipine may increase the hypotensive activities of Efonidipine.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Felodipine.	Approved, Investigational
Eltrombopag	The metabolism of Eltrombopag can be decreased when combined with Felodipine.	Approved
Empagliflozin	The risk or severity of adverse effects can be increased when Felodipine is combined with Empagliflozin.	Approved
Enalapril	The risk or severity of adverse effects can be increased when Enalapril is combined with Felodipine.	Approved, Vet Approved
Enalaprilat	Felodipine may increase the hypotensive activities of Enalaprilat.	Approved
Enzalutamide	The serum concentration of Felodipine can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The serum concentration of Epinastine can be increased when it is combined with Felodipine.	Approved, Investigational
Eplerenone	The risk or severity of adverse effects can be increased when Eplerenone is combined with Felodipine.	Approved
Epoprostenol	Felodipine may increase the hypotensive activities of Epoprostenol.	Approved
Eprosartan	The risk or severity of adverse effects can be increased when Eprosartan is combined with Felodipine.	Approved
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Felodipine.	Approved, Investigational
Erythromycin	The metabolism of Felodipine can be decreased when combined with Erythromycin.	Approved, Vet Approved
Eslicarbazepine acetate	The serum concentration of Felodipine can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esmolol	The risk or severity of adverse effects can be increased when Esmolol is combined with Felodipine.	Approved
Estradiol	The serum concentration of Estradiol can be increased when it is combined with Felodipine.	Approved, Investigational, Vet Approved
Estriol	The serum concentration of Estriol can be increased when it is combined with Felodipine.	Approved, Vet Approved
Estrone	The serum concentration of Estrone can be increased when it is combined with Felodipine.	Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Felodipine.	Approved
Etacrynic acid	The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Felodipine.	Approved
Ethinyl Estradiol	The serum concentration of Ethinyl Estradiol can be increased when it is combined with Felodipine.	Approved
Etoposide	The serum concentration of Etoposide can be increased when it is combined with Felodipine.	Approved
Etravirine	The serum concentration of Felodipine can be decreased when it is combined with Etravirine.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Felodipine.	Approved
Ezetimibe	The serum concentration of Ezetimibe can be increased when it is combined with Felodipine.	Approved
Fenoldopam	Fenoldopam may increase the hypotensive activities of Felodipine.	Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Felodipine.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be increased when it is combined with Felodipine.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be increased when it is combined with Felodipine.	Approved
Fimasartan	The risk or severity of adverse effects can be increased when Felodipine is combined with Fimasartan.	Approved
Fluconazole	The serum concentration of Felodipine can be increased when it is combined with Fluconazole.	Approved
Flucytosine	The risk or severity of adverse effects can be increased when Flucytosine is combined with Felodipine.	Approved
Fluorouracil	The metabolism of Fluorouracil can be decreased when combined with Felodipine.	Approved
Fluticasone furoate	The serum concentration of Fluticasone furoate can be increased when it is combined with Felodipine.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Felodipine.	Approved
Fluvoxamine	The metabolism of Felodipine can be decreased when combined with Fluvoxamine.	Approved, Investigational
Fosamprenavir	The metabolism of Felodipine can be decreased when combined with Fosamprenavir.	Approved
Fosaprepitant	The serum concentration of Felodipine can be increased when it is combined with Fosaprepitant.	Approved
Fosinopril	The risk or severity of adverse effects can be increased when Fosinopril is combined with Felodipine.	Approved
Fosphenytoin	The serum concentration of Fosphenytoin can be increased when it is combined with Felodipine.	Approved
Furazolidone	Furazolidone may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Furosemide	The risk or severity of adverse effects can be increased when Furosemide is combined with Felodipine.	Approved, Vet Approved
Fusidic Acid	The serum concentration of Felodipine can be increased when it is combined with Fusidic Acid.	Approved
Gefitinib	The serum concentration of Gefitinib can be increased when it is combined with Felodipine.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be increased when it is combined with Felodipine.	Approved
Glyphosate	The risk or severity of adverse effects can be increased when Glyphosate is combined with Felodipine.	Experimental
Grazoprevir	The serum concentration of Grazoprevir can be increased when it is combined with Felodipine.	Approved
Grepafloxacin	The serum concentration of Grepafloxacin can be increased when it is combined with Felodipine.	Withdrawn
Griseofulvin	The risk or severity of adverse effects can be increased when Griseofulvin is combined with Felodipine.	Approved, Vet Approved
Guanabenz	Guanabenz may increase the hypotensive activities of Felodipine.	Approved
Guanadrel	Guanadrel may increase the hypotensive activities of Felodipine.	Approved
Guanethidine	Felodipine may increase the hypotensive activities of Guanethidine.	Approved
Guanfacine	The risk or severity of adverse effects can be increased when Guanfacine is combined with Felodipine.	Approved, Investigational
Halofantrine	The metabolism of Halofantrine can be decreased when combined with Felodipine.	Approved
Haloperidol	The serum concentration of Haloperidol can be increased when it is combined with Felodipine.	Approved
Haloprogin	The risk or severity of adverse effects can be increased when Haloprogin is combined with Felodipine.	Approved, Withdrawn
Halothane	The risk or severity of adverse effects can be increased when Felodipine is combined with Halothane.	Approved, Vet Approved
Hexamethonium	Felodipine may increase the hypotensive activities of Hexamethonium.	Experimental
Hexetidine	The risk or severity of adverse effects can be increased when Hexetidine is combined with Felodipine.	Approved
Hexobarbital	Hexobarbital may increase the hypotensive activities of Felodipine.	Approved
Hydracarbazine	Hydracarbazine may increase the hypotensive activities of Felodipine.	Experimental
Hydralazine	The risk or severity of adverse effects can be increased when Felodipine is combined with Hydralazine.	Approved
Hydrochlorothiazide	The risk or severity of adverse effects can be increased when Hydrochlorothiazide is combined with Felodipine.	Approved, Vet Approved
Hydrocortisone	The serum concentration of Hydrocortisone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Hydroflumethiazide	Hydroflumethiazide may increase the hypotensive activities of Felodipine.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be increased when it is combined with Felodipine.	Approved
Idelalisib	The serum concentration of Felodipine can be increased when it is combined with Idelalisib.	Approved
Ifosfamide	The metabolism of Ifosfamide can be decreased when combined with Felodipine.	Approved
Iloprost	Iloprost may increase the hypotensive activities of Felodipine.	Approved, Investigational
Imatinib	The metabolism of Felodipine can be decreased when combined with Imatinib.	Approved
Imidapril	The risk or severity of adverse effects can be increased when Felodipine is combined with Imidapril.	Investigational
Imipramine	The serum concentration of Imipramine can be increased when it is combined with Felodipine.	Approved
Indacaterol	The serum concentration of Indacaterol can be increased when it is combined with Felodipine.	Approved
Indapamide	The risk or severity of adverse effects can be increased when Indapamide is combined with Felodipine.	Approved
Indenolol	Felodipine may increase the hypotensive activities of Indenolol.	Withdrawn
Indinavir	The metabolism of Felodipine can be decreased when combined with Indinavir.	Approved
Indomethacin	The serum concentration of Indomethacin can be increased when it is combined with Felodipine.	Approved, Investigational
Indoramin	Felodipine may increase the hypotensive activities of Indoramin.	Withdrawn
Iproclozide	Iproclozide may increase the hypotensive activities of Felodipine.	Withdrawn
Iproniazid	Iproniazid may increase the hypotensive activities of Felodipine.	Withdrawn
Irbesartan	The risk or severity of adverse effects can be increased when Felodipine is combined with Irbesartan.	Approved, Investigational
Irinotecan	The serum concentration of Irinotecan can be increased when it is combined with Felodipine.	Approved, Investigational
Isavuconazonium	The metabolism of Felodipine can be decreased when combined with Isavuconazonium.	Approved, Investigational
Isocarboxazid	Isocarboxazid may increase the hypotensive activities of Felodipine.	Approved
Isoconazole	The risk or severity of adverse effects can be increased when Isoconazole is combined with Felodipine.	Approved
Isoflurane	The risk or severity of adverse effects can be increased when Felodipine is combined with Isoflurane.	Approved, Vet Approved
Isosorbide Dinitrate	The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Felodipine.	Approved
Isosorbide Mononitrate	The risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Felodipine.	Approved
Isoxsuprine	The risk or severity of adverse effects can be increased when Felodipine is combined with Isoxsuprine.	Approved, Withdrawn
Isradipine	The risk or severity of adverse effects can be increased when Isradipine is combined with Felodipine.	Approved
Itraconazole	The serum concentration of Felodipine can be increased when it is combined with Itraconazole.	Approved, Investigational
Ivacaftor	The serum concentration of Felodipine can be increased when it is combined with Ivacaftor.	Approved
Ivermectin	The serum concentration of Ivermectin can be increased when it is combined with Felodipine.	Approved, Vet Approved
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Felodipine.	Approved
Josamycin	The metabolism of Felodipine can be decreased when combined with Josamycin.	Approved
Ketamine	The metabolism of Ketamine can be decreased when combined with Felodipine.	Approved, Vet Approved
Ketanserin	Felodipine may increase the hypotensive activities of Ketanserin.	Investigational
Ketazolam	The serum concentration of Ketazolam can be increased when it is combined with Felodipine.	Approved
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Felodipine.	Approved
Ketoconazole	The serum concentration of Felodipine can be increased when it is combined with Ketoconazole.	Approved, Investigational
Ketoconazole	The metabolism of Felodipine can be decreased when combined with Ketoconazole.	Approved, Investigational
Kitasamycin	The metabolism of Felodipine can be decreased when combined with Kitasamycin.	Experimental
Labetalol	The risk or severity of adverse effects can be increased when Labetalol is combined with Felodipine.	Approved
Lacidipine	Felodipine may increase the hypotensive activities of Lacidipine.	Approved
Lamivudine	The serum concentration of Lamivudine can be increased when it is combined with Felodipine.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be increased when it is combined with Felodipine.	Approved, Investigational
Lansoprazole	The serum concentration of Lansoprazole can be increased when it is combined with Felodipine.	Approved, Investigational
Lapatinib	The metabolism of Lapatinib can be decreased when combined with Felodipine.	Approved, Investigational
Latanoprost	Latanoprost may increase the hypotensive activities of Felodipine.	Approved, Investigational
Ledipasvir	The serum concentration of Ledipasvir can be increased when it is combined with Felodipine.	Approved
Lenalidomide	The serum concentration of Lenalidomide can be increased when it is combined with Felodipine.	Approved
Lenvatinib	The serum concentration of Lenvatinib can be increased when it is combined with Felodipine.	Approved
Lercanidipine	Lercanidipine may increase the hypotensive activities of Felodipine.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be increased when it is combined with Felodipine.	Approved, Investigational
Levobunolol	The risk or severity of adverse effects can be increased when Felodipine is combined with Levobunolol.	Approved
Levobupivacaine	The risk or severity of adverse effects can be increased when Felodipine is combined with Levobupivacaine.	Approved
Levodopa	Felodipine may increase the orthostatic hypotensive activities of Levodopa.	Approved
Levofloxacin	The serum concentration of Levofloxacin can be increased when it is combined with Felodipine.	Approved, Investigational
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Felodipine.	Approved
Levosimendan	The risk or severity of adverse effects can be increased when Felodipine is combined with Levosimendan.	Approved, Investigational
Licofelone	The metabolism of Licofelone can be decreased when combined with Felodipine.	Investigational
Lidocaine	The metabolism of Lidocaine can be decreased when combined with Felodipine.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be increased when it is combined with Felodipine.	Approved
Lisinopril	The risk or severity of adverse effects can be increased when Lisinopril is combined with Felodipine.	Approved, Investigational
Lofexidine	Felodipine may increase the hypotensive activities of Lofexidine.	Approved, Investigational
Loperamide	The serum concentration of Loperamide can be increased when it is combined with Felodipine.	Approved
Lopinavir	The metabolism of Felodipine can be decreased when combined with Lopinavir.	Approved
Loratadine	The metabolism of Loratadine can be decreased when combined with Felodipine.	Approved
Losartan	The risk or severity of adverse effects can be increased when Losartan is combined with Felodipine.	Approved
Lovastatin	The metabolism of Felodipine can be decreased when combined with Lovastatin.	Approved, Investigational
Luliconazole	The serum concentration of Felodipine can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The metabolism of Felodipine can be increased when combined with Lumacaftor.	Approved
Macitentan	Felodipine may increase the hypotensive activities of Macitentan.	Approved
Magnesium Hydroxide	The risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium hydroxide.	Approved
Magnesium oxide	The risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium oxide.	Approved
Magnesium salicylate	The risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium salicylate.	Approved
Magnesium Sulfate	The risk or severity of adverse effects can be increased when Felodipine is combined with Magnesium Sulfate.	Approved, Vet Approved
Manidipine	Felodipine may increase the hypotensive activities of Manidipine.	Approved
Mannitol	The risk or severity of adverse effects can be increased when Mannitol is combined with Felodipine.	Approved, Investigational
Mebanazine	Mebanazine may increase the hypotensive activities of Felodipine.	Withdrawn
Mecamylamine	The risk or severity of adverse effects can be increased when Mecamylamine is combined with Felodipine.	Approved
Mefenamic acid	The metabolism of Mefenamic acid can be decreased when combined with Felodipine.	Approved
Melatonin	Melatonin may decrease the antihypertensive activities of Felodipine.	Approved, Nutraceutical, Vet Approved
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Felodipine.	Approved, Vet Approved
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Felodipine.	Investigational, Withdrawn
Methadone	The metabolism of Methadone can be decreased when combined with Felodipine.	Approved
Methazolamide	The risk or severity of adverse effects can be increased when Methazolamide is combined with Felodipine.	Approved
Methohexital	Methohexital may increase the hypotensive activities of Felodipine.	Approved
Methotrexate	The serum concentration of Methotrexate can be increased when it is combined with Felodipine.	Approved
Methyclothiazide	The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Felodipine.	Approved
Methyldopa	The risk or severity of adverse effects can be increased when Methyldopa is combined with Felodipine.	Approved
Methylene blue	Methylene blue may increase the hypotensive activities of Felodipine.	Investigational
Methylphenidate	Methylphenidate may decrease the antihypertensive activities of Felodipine.	Approved, Investigational
Methylphenobarbital	Methylphenobarbital may increase the hypotensive activities of Felodipine.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Metipranolol	The risk or severity of adverse effects can be increased when Felodipine is combined with Metipranolol.	Approved
Metolazone	The risk or severity of adverse effects can be increased when Metolazone is combined with Felodipine.	Approved
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Felodipine.	Approved, Investigational
Metyrosine	Felodipine may increase the hypotensive activities of Metyrosine.	Approved
Mevastatin	The risk or severity of adverse effects can be increased when Mevastatin is combined with Felodipine.	Experimental
Mibefradil	Felodipine may increase the hypotensive activities of Mibefradil.	Withdrawn
Micafungin	The risk or severity of adverse effects can be increased when Micafungin is combined with Felodipine.	Approved, Investigational
Miconazole	The risk or severity of adverse effects can be increased when Miconazole is combined with Felodipine.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Felodipine.	Approved, Illicit
Mifepristone	The serum concentration of Felodipine can be increased when it is combined with Mifepristone.	Approved, Investigational
Miltefosine	The risk or severity of adverse effects can be increased when Miltefosine is combined with Felodipine.	Approved
Minaprine	Minaprine may increase the hypotensive activities of Felodipine.	Approved
Minoxidil	The risk or severity of adverse effects can be increased when Minoxidil is combined with Felodipine.	Approved
Mirabegron	The serum concentration of Mirabegron can be increased when it is combined with Felodipine.	Approved
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Felodipine.	Approved
Mitotane	The serum concentration of Felodipine can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be increased when it is combined with Felodipine.	Approved, Investigational
Mivacurium	Felodipine may increase the neuromuscular blocking activities of Mivacurium.	Approved
Moclobemide	Moclobemide may increase the hypotensive activities of Felodipine.	Approved
Modafinil	The serum concentration of Felodipine can be decreased when it is combined with Modafinil.	Approved, Investigational
Moexipril	The risk or severity of adverse effects can be increased when Moexipril is combined with Felodipine.	Approved
Molsidomine	Molsidomine may increase the hypotensive activities of Felodipine.	Approved
Monensin	The risk or severity of adverse effects can be increased when Monensin is combined with Felodipine.	Vet Approved
Morphine	The serum concentration of Morphine can be increased when it is combined with Felodipine.	Approved, Investigational
Moxonidine	Felodipine may increase the hypotensive activities of Moxonidine.	Approved
muraglitazar	The metabolism of muraglitazar can be decreased when combined with Felodipine.	Investigational
Mycophenolate mofetil	The serum concentration of Mycophenolate mofetil can be increased when it is combined with Felodipine.	Approved, Investigational
Myxothiazol	The risk or severity of adverse effects can be increased when Myxothiazol is combined with Felodipine.	Experimental
Nabilone	The risk or severity of adverse effects can be increased when Felodipine is combined with Nabilone.	Approved, Investigational
Nadolol	The risk or severity of adverse effects can be increased when Felodipine is combined with Nadolol.	Approved
Nafcillin	The metabolism of Felodipine can be increased when combined with Nafcillin.	Approved
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Felodipine.	Approved
Naftopidil	Felodipine may increase the hypotensive activities of Naftopidil.	Investigational
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Felodipine.	Approved
Naloxone	The serum concentration of Naloxone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Naproxen	The metabolism of Naproxen can be decreased when combined with Felodipine.	Approved, Vet Approved
Natamycin	The risk or severity of adverse effects can be increased when Natamycin is combined with Felodipine.	Approved
Nebivolol	The risk or severity of adverse effects can be increased when Felodipine is combined with Nebivolol.	Approved, Investigational
Nefazodone	The metabolism of Felodipine can be decreased when combined with Nefazodone.	Approved, Withdrawn
Nelfinavir	The metabolism of Felodipine can be decreased when combined with Nelfinavir.	Approved
Nesiritide	The risk or severity of adverse effects can be increased when Felodipine is combined with Nesiritide.	Approved, Investigational
Netupitant	The serum concentration of Felodipine can be increased when it is combined with Netupitant.	Approved
Nevirapine	The metabolism of Felodipine can be increased when combined with Nevirapine.	Approved
Nialamide	Nialamide may increase the hypotensive activities of Felodipine.	Withdrawn
Nicardipine	The risk or severity of adverse effects can be increased when Nicardipine is combined with Felodipine.	Approved
Nicorandil	Nicorandil may increase the hypotensive activities of Felodipine.	Approved
Nicotine	The metabolism of Nicotine can be decreased when combined with Felodipine.	Approved
Nifedipine	The risk or severity of adverse effects can be increased when Felodipine is combined with Nifedipine.	Approved
Niguldipine	Felodipine may increase the hypotensive activities of Niguldipine.	Experimental
Nilotinib	The metabolism of Felodipine can be decreased when combined with Nilotinib.	Approved, Investigational
Nilvadipine	Felodipine may increase the hypotensive activities of Nilvadipine.	Approved
Nimodipine	The risk or severity of adverse effects can be increased when Nimodipine is combined with Felodipine.	Approved
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Felodipine.	Approved
Nisoldipine	The risk or severity of adverse effects can be increased when Nisoldipine is combined with Felodipine.	Approved
Nitrendipine	Felodipine may increase the hypotensive activities of Nitrendipine.	Approved
Nitric Oxide	The risk or severity of adverse effects can be increased when Felodipine is combined with Nitric Oxide.	Approved
Nitroglycerin	The risk or severity of adverse effects can be increased when Nitroglycerin is combined with Felodipine.	Approved, Investigational
Nitroprusside	Felodipine may increase the hypotensive activities of Nitroprusside.	Approved
Nitroxoline	The risk or severity of adverse effects can be increased when Nitroxoline is combined with Felodipine.	Approved
Nizatidine	The serum concentration of Nizatidine can be increased when it is combined with Felodipine.	Approved
Nystatin	The risk or severity of adverse effects can be increased when Nystatin is combined with Felodipine.	Approved, Vet Approved
Obinutuzumab	Felodipine may increase the hypotensive activities of Obinutuzumab.	Approved
Octamoxin	Octamoxin may increase the hypotensive activities of Felodipine.	Withdrawn
Olanzapine	The serum concentration of Olanzapine can be increased when it is combined with Felodipine.	Approved, Investigational
Olaparib	The metabolism of Felodipine can be decreased when combined with Olaparib.	Approved
Oleandomycin	The metabolism of Felodipine can be decreased when combined with Oleandomycin.	Vet Approved
Olmesartan	The risk or severity of adverse effects can be increased when Olmesartan is combined with Felodipine.	Approved, Investigational
Olodaterol	The metabolism of Olodaterol can be decreased when combined with Felodipine.	Approved
Omapatrilat	Omapatrilat may increase the hypotensive activities of Felodipine.	Investigational
Ombitasvir	The serum concentration of Ombitasvir can be increased when it is combined with Felodipine.	Approved
Omeprazole	The metabolism of Omeprazole can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Osimertinib	The serum concentration of Felodipine can be increased when it is combined with Osimertinib.	Approved
Oxiconazole	The risk or severity of adverse effects can be increased when Oxiconazole is combined with Felodipine.	Approved
Oxprenolol	Felodipine may increase the hypotensive activities of Oxprenolol.	Approved
Paclitaxel	The serum concentration of Paclitaxel can be increased when it is combined with Felodipine.	Approved, Vet Approved
pafuramidine	The risk or severity of adverse effects can be increased when pafuramidine is combined with Felodipine.	Investigational
Palbociclib	The serum concentration of Felodipine can be increased when it is combined with Palbociclib.	Approved
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Felodipine.	Approved, Investigational
Papaverine	The risk or severity of adverse effects can be increased when Felodipine is combined with Papaverine.	Approved
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Felodipine.	Approved
Pargyline	Pargyline may increase the hypotensive activities of Felodipine.	Approved
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Felodipine.	Approved
Penbutolol	The risk or severity of adverse effects can be increased when Felodipine is combined with Penbutolol.	Approved, Investigational
Pentamidine	The risk or severity of adverse effects can be increased when Pentamidine is combined with Felodipine.	Approved
Pentobarbital	The metabolism of Felodipine can be increased when combined with Pentobarbital.	Approved, Vet Approved
Pentolinium	Felodipine may increase the hypotensive activities of Pentolinium.	Approved
Pentoxifylline	Pentoxifylline may increase the hypotensive activities of Felodipine.	Approved, Investigational
Perindopril	The risk or severity of adverse effects can be increased when Perindopril is combined with Felodipine.	Approved
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Felodipine.	Approved
Phenelzine	Phenelzine may increase the hypotensive activities of Felodipine.	Approved
Pheniprazine	Pheniprazine may increase the hypotensive activities of Felodipine.	Withdrawn
Phenobarbital	The metabolism of Felodipine can be increased when combined with Phenobarbital.	Approved
Phenoxybenzamine	Phenoxybenzamine may increase the hypotensive activities of Felodipine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypotensive activities of Felodipine.	Withdrawn
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Felodipine.	Approved
Phentolamine	Phentolamine may increase the hypotensive activities of Felodipine.	Approved
Phenytoin	The serum concentration of Phenytoin can be increased when it is combined with Felodipine.	Approved, Vet Approved
Pinacidil	Felodipine may increase the hypotensive activities of Pinacidil.	Withdrawn
Pindolol	The risk or severity of adverse effects can be increased when Pindolol is combined with Felodipine.	Approved
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Felodipine.	Approved, Investigational
Pipamperone	The risk or severity of adverse effects can be increased when Felodipine is combined with Pipamperone.	Approved
Pirlindole	Pirlindole may increase the hypotensive activities of Felodipine.	Approved
Piroxicam	The metabolism of Piroxicam can be decreased when combined with Felodipine.	Approved, Investigational
Pitavastatin	The serum concentration of Pitavastatin can be increased when it is combined with Felodipine.	Approved
Pivhydrazine	Pivhydrazine may increase the hypotensive activities of Felodipine.	Withdrawn
Polythiazide	Felodipine may increase the hypotensive activities of Polythiazide.	Approved
Pomalidomide	The serum concentration of Pomalidomide can be increased when it is combined with Felodipine.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Felodipine.	Approved
Posaconazole	The metabolism of Felodipine can be decreased when combined with Posaconazole.	Approved, Investigational, Vet Approved
Pramipexole	The risk or severity of adverse effects can be increased when Felodipine is combined with Pramipexole.	Approved, Investigational
Pravastatin	The serum concentration of Pravastatin can be increased when it is combined with Felodipine.	Approved
Prazosin	The risk or severity of adverse effects can be increased when Prazosin is combined with Felodipine.	Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Primidone	The metabolism of Felodipine can be increased when combined with Primidone.	Approved, Vet Approved
Progesterone	The serum concentration of Progesterone can be increased when it is combined with Felodipine.	Approved, Vet Approved
Propofol	The metabolism of Propofol can be decreased when combined with Felodipine.	Approved, Investigational, Vet Approved
Propranolol	The risk or severity of adverse effects can be increased when Propranolol is combined with Felodipine.	Approved, Investigational
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Felodipine.	Approved
Quetiapine	The risk or severity of adverse effects can be increased when Felodipine is combined with Quetiapine.	Approved
Quinapril	The risk or severity of adverse effects can be increased when Quinapril is combined with Felodipine.	Approved, Investigational
Quinidine	The serum concentration of Quinidine can be decreased when it is combined with Felodipine.	Approved
Quinine	Quinine may increase the hypotensive activities of Felodipine.	Approved
Radicicol	The risk or severity of adverse effects can be increased when Radicicol is combined with Felodipine.	Experimental
Ramipril	The risk or severity of adverse effects can be increased when Ramipril is combined with Felodipine.	Approved
Ranitidine	The serum concentration of Ranitidine can be increased when it is combined with Felodipine.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Felodipine.	Approved, Investigational
Rapacuronium	Felodipine may increase the neuromuscular blocking activities of Rapacuronium.	Withdrawn
Rasagiline	Rasagiline may increase the hypotensive activities of Felodipine.	Approved
Remifentanil	The risk or severity of adverse effects can be increased when Felodipine is combined with Remifentanil.	Approved
Remikiren	Remikiren may increase the hypotensive activities of Felodipine.	Approved
Repaglinide	The metabolism of Repaglinide can be decreased when combined with Felodipine.	Approved, Investigational
Rescinnamine	Felodipine may increase the hypotensive activities of Rescinnamine.	Approved
Reserpine	The risk or severity of adverse effects can be increased when Reserpine is combined with Felodipine.	Approved
Rifabutin	The metabolism of Felodipine can be increased when combined with Rifabutin.	Approved
Rifampicin	The metabolism of Felodipine can be increased when combined with Rifampicin.	Approved
Rifapentine	The metabolism of Felodipine can be increased when combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Felodipine.	Approved, Investigational
Rilmenidine	Felodipine may increase the hypotensive activities of Rilmenidine.	Investigational
Riociguat	The risk or severity of adverse effects can be increased when Felodipine is combined with Riociguat.	Approved
Risperidone	Felodipine may increase the hypotensive activities of Risperidone.	Approved, Investigational
Ritonavir	The metabolism of Felodipine can be decreased when combined with Ritonavir.	Approved, Investigational
Rituximab	Felodipine may increase the hypotensive activities of Rituximab.	Approved
Rivaroxaban	The serum concentration of Rivaroxaban can be increased when it is combined with Felodipine.	Approved
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Felodipine.	Investigational, Withdrawn
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Felodipine.	Approved, Investigational
Ropinirole	The risk or severity of adverse effects can be increased when Felodipine is combined with Ropinirole.	Approved, Investigational
Ropivacaine	The risk or severity of adverse effects can be increased when Felodipine is combined with Ropivacaine.	Approved
Rosiglitazone	The metabolism of Rosiglitazone can be decreased when combined with Felodipine.	Approved, Investigational
Rotigotine	The risk or severity of adverse effects can be increased when Felodipine is combined with Rotigotine.	Approved
Sacubitril	The risk or severity of adverse effects can be increased when Felodipine is combined with Sacubitril.	Approved
Safrazine	Safrazine may increase the hypotensive activities of Felodipine.	Withdrawn
Salicylhydroxamic Acid	The risk or severity of adverse effects can be increased when Salicylhydroxamic Acid is combined with Felodipine.	Experimental
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Felodipine.	Approved, Vet Approved
Saprisartan	Felodipine may increase the hypotensive activities of Saprisartan.	Experimental
Saquinavir	The metabolism of Felodipine can be decreased when combined with Saquinavir.	Approved, Investigational
Secobarbital	Secobarbital may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Selegiline	Selegiline may increase the hypotensive activities of Felodipine.	Approved, Investigational, Vet Approved
Selexipag	The serum concentration of Selexipag can be increased when it is combined with Felodipine.	Approved
Seratrodast	The metabolism of Seratrodast can be decreased when combined with Felodipine.	Approved
Sertaconazole	The risk or severity of adverse effects can be increased when Sertaconazole is combined with Felodipine.	Approved
Sevoflurane	The risk or severity of adverse effects can be increased when Felodipine is combined with Sevoflurane.	Approved, Vet Approved
Sildenafil	Sildenafil may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Felodipine.	Approved
Siltuximab	The serum concentration of Felodipine can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Felodipine can be increased when it is combined with Simeprevir.	Approved
Simvastatin	The metabolism of Simvastatin can be decreased when combined with Felodipine.	Approved
Sinefungin	The risk or severity of adverse effects can be increased when Sinefungin is combined with Felodipine.	Experimental
Sirolimus	The risk or severity of adverse effects can be increased when Sirolimus is combined with Felodipine.	Approved, Investigational
Sitagliptin	The serum concentration of Sitagliptin can be increased when it is combined with Felodipine.	Approved, Investigational
Sitaxentan	Felodipine may increase the hypotensive activities of Sitaxentan.	Approved, Investigational, Withdrawn
Sodium Nitrite	The risk or severity of adverse effects can be increased when Felodipine is combined with Sodium Nitrite.	Approved
Sofosbuvir	The serum concentration of Sofosbuvir can be increased when it is combined with Felodipine.	Approved
Solithromycin	The metabolism of Felodipine can be decreased when combined with Solithromycin.	Investigational
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Felodipine.	Approved, Investigational
Sotalol	The risk or severity of adverse effects can be increased when Sotalol is combined with Felodipine.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be increased when it is combined with Felodipine.	Approved
Sphingosine	The serum concentration of Sphingosine can be increased when it is combined with Felodipine.	Experimental
Spirapril	Felodipine may increase the hypotensive activities of Spirapril.	Approved
Spironolactone	The risk or severity of adverse effects can be increased when Spironolactone is combined with Felodipine.	Approved
St. John's Wort	The serum concentration of Felodipine can be decreased when it is combined with St. John's Wort.	Nutraceutical
Stiripentol	The serum concentration of Felodipine can be increased when it is combined with Stiripentol.	Approved
Streptokinase	The risk or severity of adverse effects can be increased when Felodipine is combined with Streptokinase.	Approved
Sufentanil	The risk or severity of adverse effects can be increased when Felodipine is combined with Sufentanil.	Approved, Investigational
Sulconazole	The risk or severity of adverse effects can be increased when Sulconazole is combined with Felodipine.	Approved
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Felodipine.	Approved, Vet Approved
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Felodipine.	Approved
Sulfisoxazole	The metabolism of Felodipine can be decreased when combined with Sulfisoxazole.	Approved, Vet Approved
Tacrolimus	The serum concentration of Tacrolimus can be increased when it is combined with Felodipine.	Approved, Investigational
Tadalafil	Tadalafil may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Tamoxifen	The serum concentration of Tamoxifen can be increased when it is combined with Felodipine.	Approved
Tamsulosin	Tamsulosin may increase the hypotensive activities of Felodipine.	Approved, Investigational
Taurocholic Acid	The serum concentration of Taurocholic Acid can be increased when it is combined with Felodipine.	Experimental
Tavaborole	The risk or severity of adverse effects can be increased when Tavaborole is combined with Felodipine.	Approved
Tazarotene	The metabolism of Tazarotene can be decreased when combined with Felodipine.	Approved, Investigational
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Felodipine.	Approved
Telaprevir	The metabolism of Felodipine can be decreased when combined with Telaprevir.	Withdrawn
Telithromycin	The metabolism of Felodipine can be decreased when combined with Telithromycin.	Approved
Telmisartan	The risk or severity of adverse effects can be increased when Telmisartan is combined with Felodipine.	Approved, Investigational
Temazepam	The metabolism of Temazepam can be decreased when combined with Felodipine.	Approved
Temocapril	Felodipine may increase the hypotensive activities of Temocapril.	Experimental, Investigational
Temsirolimus	The serum concentration of Temsirolimus can be increased when it is combined with Felodipine.	Approved
Terazosin	The risk or severity of adverse effects can be increased when Felodipine is combined with Terazosin.	Approved
Terbinafine	The risk or severity of adverse effects can be increased when Terbinafine is combined with Felodipine.	Approved, Investigational, Vet Approved
Terconazole	The risk or severity of adverse effects can be increased when Terconazole is combined with Felodipine.	Approved
Terlipressin	Felodipine may increase the hypotensive activities of Terlipressin.	Approved, Investigational
Testosterone	The metabolism of Testosterone can be decreased when combined with Felodipine.	Approved, Investigational
Thalidomide	The risk or severity of adverse effects can be increased when Felodipine is combined with Thalidomide.	Approved, Investigational, Withdrawn
Theophylline	The metabolism of Theophylline can be decreased when combined with Felodipine.	Approved
Thiamylal	Thiamylal may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Thiopental	Thiopental may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Felodipine.	Withdrawn
Thymol	The risk or severity of adverse effects can be increased when Thymol is combined with Felodipine.	Approved
Tibolone	Felodipine may increase the hypotensive activities of Tibolone.	Approved
Ticagrelor	The serum concentration of Ticagrelor can be increased when it is combined with Felodipine.	Approved
Ticlopidine	The metabolism of Felodipine can be decreased when combined with Ticlopidine.	Approved
Ticrynafen	Felodipine may increase the hypotensive activities of Ticrynafen.	Withdrawn
Timolol	The risk or severity of adverse effects can be increased when Timolol is combined with Felodipine.	Approved
Tioconazole	The risk or severity of adverse effects can be increased when Tioconazole is combined with Felodipine.	Approved
Tizanidine	The risk or severity of adverse effects can be increased when Tizanidine is combined with Felodipine.	Approved
Tocilizumab	The serum concentration of Felodipine can be decreased when it is combined with Tocilizumab.	Approved
Tolazoline	Tolazoline may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Tolbutamide	The metabolism of Tolbutamide can be decreased when combined with Felodipine.	Approved
Tolcapone	The risk or severity of adverse effects can be increased when Felodipine is combined with Tolcapone.	Approved, Withdrawn
Tolnaftate	The risk or severity of adverse effects can be increased when Tolnaftate is combined with Felodipine.	Approved, Vet Approved
Toloxatone	Toloxatone may increase the hypotensive activities of Felodipine.	Approved
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Felodipine.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Felodipine.	Approved, Investigational
Torasemide	The risk or severity of adverse effects can be increased when Torasemide is combined with Felodipine.	Approved
Toremifene	The serum concentration of Toremifene can be increased when it is combined with Felodipine.	Approved, Investigational
Trandolapril	The risk or severity of adverse effects can be increased when Trandolapril is combined with Felodipine.	Approved
Trans-2-Phenylcyclopropylamine	Trans-2-Phenylcyclopropylamine may increase the hypotensive activities of Felodipine.	Experimental
Tranylcypromine	Tranylcypromine may increase the hypotensive activities of Felodipine.	Approved
Trastuzumab emtansine	The serum concentration of Trastuzumab emtansine can be increased when it is combined with Felodipine.	Approved
Travoprost	Travoprost may increase the hypotensive activities of Felodipine.	Approved
Treprostinil	Treprostinil may increase the hypotensive activities of Felodipine.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Felodipine.	Approved, Investigational, Nutraceutical
Triamterene	The risk or severity of adverse effects can be increased when Triamterene is combined with Felodipine.	Approved
Trichlormethiazide	Trichlormethiazide may increase the hypotensive activities of Felodipine.	Approved, Vet Approved
Trimazosin	Felodipine may increase the hypotensive activities of Trimazosin.	Experimental
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Felodipine.	Approved
Trimethaphan	Felodipine may increase the hypotensive activities of Trimethaphan.	Approved
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Felodipine.	Approved, Vet Approved
Trimetrexate	The risk or severity of adverse effects can be increased when Trimetrexate is combined with Felodipine.	Approved, Investigational
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Felodipine.	Withdrawn
Tylosin	The metabolism of Felodipine can be decreased when combined with Tylosin.	Vet Approved
Udenafil	Udenafil may increase the antihypertensive activities of Felodipine.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Felodipine.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be increased when it is combined with Felodipine.	Approved
Unoprostone	Felodipine may increase the hypotensive activities of Unoprostone.	Approved
Valsartan	The risk or severity of adverse effects can be increased when Valsartan is combined with Felodipine.	Approved, Investigational
Vardenafil	Vardenafil may increase the antihypertensive activities of Felodipine.	Approved
Vecuronium	The serum concentration of Vecuronium can be increased when it is combined with Felodipine.	Approved
Venetoclax	The serum concentration of Venetoclax can be increased when it is combined with Felodipine.	Approved
Venlafaxine	The metabolism of Felodipine can be decreased when combined with Venlafaxine.	Approved
Verapamil	The risk or severity of adverse effects can be increased when Verapamil is combined with Felodipine.	Approved
Vinblastine	The serum concentration of Vinblastine can be increased when it is combined with Felodipine.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Felodipine.	Approved, Investigational
Vinpocetine	Felodipine may increase the hypotensive activities of Vinpocetine.	Investigational
Vismodegib	The serum concentration of Vismodegib can be increased when it is combined with Felodipine.	Approved
Voriconazole	The metabolism of Felodipine can be decreased when combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Felodipine.	Approved
Warfarin	The metabolism of Warfarin can be decreased when combined with Felodipine.	Approved
Xylometazoline	Felodipine may increase the hypotensive activities of Xylometazoline.	Approved
Yohimbine	Yohimbine may decrease the antihypertensive activities of Felodipine.	Approved, Vet Approved
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Felodipine.	Approved, Investigational
Zidovudine	The serum concentration of Zidovudine can be increased when it is combined with Felodipine.	Approved
Ziprasidone	The metabolism of Felodipine can be decreased when combined with Ziprasidone.	Approved
Zopiclone	The metabolism of Zopiclone can be decreased when combined with Felodipine.	Approved

Food Interactions

Grapefruit down regulates post-translational expression of CYP3A4, the major metabolizing enzyme of nifedipine. Grapefruit, in all forms (e.g. whole fruit, juice and rind), can significantly increase serum levels of nifedipine and may cause toxicity. Avoid grapefruit products while on this medication.
Take without regard to meals.

References

Synthesis Reference

Vinay Sharma, "Preparation of micron-size felodipine particles by microfluidization." U.S. Patent US20020086061, issued July 04, 2002.

US20020086061

General References

Dunselman PH, Edgar B: Felodipine clinical pharmacokinetics. Clin Pharmacokinet. 1991 Dec;21(6):418-30. [PubMed:1782737 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB15158
KEGG Drug	D00319
PubChem Compound	3333
PubChem Substance	46506968
ChemSpider	3216
BindingDB	189379
ChEBI	585948
ChEMBL	CHEMBL1480
Therapeutic Targets Database	DAP000487
PharmGKB	PA449591
IUPHAR	4190
Guide to Pharmacology	4190
Drug Product Database	1249
RxList	http://www.rxlist.com/cgi/generic2/felo.htm
Drugs.com	http://www.drugs.com/cdi/felodipine.html
PDRhealth	http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=ple1339.html&contentName=Plendil&contentId=593
Wikipedia	Felodipine

ATC Codes

C08CA02 — Felodipine

C09BB05 — Ramipril and felodipine

AHFS Codes

24:28.08

PDB Entries

Not Available

FDA label

Download (228 KB)

MSDS

Download (55.4 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Treatment	Food-Drug Interactions	1
3	Completed	Prevention	Atherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus	1
3	Completed	Treatment	BMI >30 kg/m2 / Hypertensive	1
4	Completed	Prevention	Disorders Related to Lung Transplantation	1
4	Completed	Treatment	Hypertensive	2
4	Completed	Treatment	Hypertensive / Left Ventricular Hypertrophy	1
4	Unknown Status	Treatment	Hypertensive / Sexual Dysfunctions	1
Not Available	Completed	Not Available	Healthy Volunteers	2
Not Available	Completed	Not Available	Hypertensive	1
Not Available	Completed	Treatment	Hypertensive	1
Not Available	Unknown Status	Basic Science	Hypertensive / Insulin Resistance / Microcirculation	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

A-S Medication Solutions LLC
AstraZeneca Inc.
Atlantic Biologicals Corporation
Bryant Ranch Prepack
Cardinal Health
Heartland Repack Services LLC
Lake Erie Medical and Surgical Supply
Liberty Pharmaceuticals
Merck & Co.
Murfreesboro Pharmaceutical Nursing Supply
Mutual Pharmaceutical Co.
Mylan
Nucare Pharmaceuticals Inc.
PD-Rx Pharmaceuticals Inc.
Physicians Total Care Inc.
Preferred Pharmaceuticals Inc.
Prepackage Specialists
Prepak Systems Inc.
Prescript Pharmaceuticals
Ranbaxy Laboratories
Resource Optimization and Innovation LLC
Richmond Pharmacy
Sandhills Packaging Inc.
UDL Laboratories
Va Cmop Dallas
Vangard Labs Inc.

Dosage forms

Form	Route	Strength
Tablet	Oral
Tablet, film coated	Oral	2.5 mg/1
Tablet, film coated, extended release	Oral	10 mg/1
Tablet, film coated, extended release	Oral	2.5 mg/1
Tablet, film coated, extended release	Oral	5 mg/1
Tablet, extended release	Oral	10 mg/1
Tablet, extended release	Oral	2.5 mg/1
Tablet, extended release	Oral	5 mg/1
Tablet, extended release	Oral	10 mg
Tablet, extended release	Oral	2.5 mg
Tablet, extended release	Oral	5 mg

Prices

Unit description	Cost	Unit
Plendil 10 mg 24 Hour tablet	3.17USD	tablet
Plendil er 10 mg tablet	3.05USD	tablet
Plendil 10 mg tablet sa	2.96USD	tablet
Felodipine 10 mg 24 Hour tablet	2.95USD	tablet
Plendil er 2.5 mg tablet	2.94USD	tablet
Felodipine er 10 mg tablet	2.72USD	tablet
Plendil er 5 mg tablet	2.6USD	tablet
Plendil 5 mg 24 Hour tablet	1.77USD	tablet
Plendil 2.5 mg 24 Hour tablet	1.76USD	tablet
Felodipine 5 mg 24 Hour tablet	1.67USD	tablet
Plendil 2.5 mg tablet sa	1.65USD	tablet
Plendil 5 mg tablet sa	1.65USD	tablet
Felodipine 2.5 mg 24 Hour tablet	1.57USD	tablet
Felodipine er 2.5 mg tablet	1.51USD	tablet
Felodipine er 5 mg tablet	1.51USD	tablet
Renedil 10 mg Extended-Release Tablet	1.22USD	tablet
Plendil 10 mg Extended-Release Tablet	1.15USD	tablet
Renedil 5 mg Extended-Release Tablet	0.81USD	tablet
Plendil 5 mg Extended-Release Tablet	0.77USD	tablet
Sandoz Felodipine 10 mg Extended-Release Tablet	0.73USD	tablet
Renedil 2.5 mg Extended-Release Tablet	0.6USD	tablet
Plendil 2.5 mg Extended-Release Tablet	0.57USD	tablet
Sandoz Felodipine 5 mg Extended-Release Tablet	0.48USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	145 °C	Not Available
water solubility	19.7 mg/L	Not Available
logP	3.86	SANGSTER (1994)
Caco2 permeability	-4.64	ADME Research, USCD

Predicted Properties

Property	Value	Source
Water Solubility	0.00715 mg/mL	ALOGPS
logP	4.36	ALOGPS
logP	3.44	ChemAxon
logS	-4.7	ALOGPS
pKa (Strongest Basic)	5.39	ChemAxon
Physiological Charge	0	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	1	ChemAxon
Polar Surface Area	64.63 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	99.2 m³·mol^-1	ChemAxon
Polarizability	38.04 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9878
Blood Brain Barrier	-	0.83
Caco-2 permeable	+	0.8867
P-glycoprotein substrate	Substrate	0.5149
P-glycoprotein inhibitor I	Inhibitor	0.8563
P-glycoprotein inhibitor II	Non-inhibitor	0.8383
Renal organic cation transporter	Non-inhibitor	0.8664
CYP450 2C9 substrate	Non-substrate	0.8357
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Substrate	0.6954
CYP450 1A2 substrate	Inhibitor	0.9106
CYP450 2C9 inhibitor	Inhibitor	0.8948
CYP450 2D6 inhibitor	Non-inhibitor	0.9232
CYP450 2C19 inhibitor	Inhibitor	0.8994
CYP450 3A4 inhibitor	Inhibitor	0.7959
CYP450 inhibitory promiscuity	High CYP Inhibitory Promiscuity	0.9304
Ames test	Non AMES toxic	0.7849
Carcinogenicity	Non-carcinogens	0.7511
Biodegradation	Not ready biodegradable	0.9527
Rat acute toxicity	2.4526 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9455
hERG inhibition (predictor II)	Non-inhibitor	0.8734

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted GC-MS	Predicted GC-MS Spectrum - GC-MS	Not Available
LC-MS/MS	LC-MS/MS Spectrum - LC-ESI-qTof , Positive	Not Available
LC-MS/MS	LC-MS/MS Spectrum - , positive	splash10-0udu-0139000000-085071c20c5d0c134d8f	View in MoNA
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as dihydropyridinecarboxylic acids and derivatives. These are compounds containing a dihydropyridine moiety bearing a carboxylic acid group.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organoheterocyclic compounds

Sub Class

Pyridines and derivatives

Direct Parent

Dihydropyridinecarboxylic acids and derivatives

Alternative Parents

Dichlorobenzenes / Dicarboxylic acids and derivatives / Aryl chlorides / Vinylogous amides / Methyl esters / Enoate esters / Amino acids and derivatives / Enamines / Dialkylamines / Azacyclic compounds

Substituents

Dihydropyridinecarboxylic acid derivative / 1,2-dichlorobenzene / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Dicarboxylic acid or derivatives / Benzenoid / Vinylogous amide

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

ethyl ester, dichlorobenzene, methyl ester, dihydropyridine (CHEBI:585948 )

Structure for DB01023 (Felodipine)

Targets

References

References

References

References

References

References

References

References

References

References

References

References

References

Enzymes

References

References

References

References

References

References

Transporters

References